No reflow : quels facteurs prédictifs ?

Chettibi, Mohamed; Benghezel, Said; Bertal, S.; Nedjar, R.; Bouraghda, Mohamed Abed; Bouafia, M.T.

doi:10.1016/j.ancard.2015.09.059

Cited by 2 publications

(1 citation statement)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…У пациентов с более выраженным классом острой сердечной недостаточности (ОСН) наблюдалась большая частота развития феномена no-/slowreflow (Killip II-IV в 1-й и 2-й группах обнаруживалась в 38,9% и 12,1% соответственно, p<0,001). При по- [8], что близко к полученному нами показателю, но, в целом, по данными литературы, частота развития феномена no-/slow-reflow варьирует от 2% до 44% [2,4,5,7,[9][10][11][12][13][14][15][16]. Такие разные данные, возможно, объясняются разными методами диагностики этого феномена, гетерогенностью генетико-демографическим факторов в исследуемых выборках пациентов.…”

Section: результатыunclassified

Clinical factors associated with the no/slow-reflow phenomenon in patients with acute coronary syndrome

Konstantinova,

Ilin,

Velikotskiy

et al. 2024

Racionalʹnaâ farmakoterapiâ v kardiologii

View full text Add to dashboard Cite

Aim. To determine the incidence of the no-reflow phenomenon in patients with acute coronary syndrome (ACS) undergoing primary percutaneous coronary intervention (PCI), and to study factors associated with its occurrence in the daily work of the City Clinical Hospital.Material and methods. Of the 2090 patients with ACS admitted to N. I. Pirogov City Clinical Hospital No.1 in the period from 01.01.2017 to 01.11.2022 there were 2 groups of patients with PCI: group 1 (n=59) included patients with initial antegrade coronary blood flow TIMI 0 and final blood flow TIMI 0-2 (with the no/ slow-reflow phenomenon); Group 2 (n=149) included patients with initial coronary blood flow TIMI 0 and final antegrade coronary blood flow TIMI 3 (without the no/slow-reflow phenomenon).Results. The no-/slow-reflow phenomenon was observed in 2.8% of cases. Patients with no-/slow-reflow phenomenon more frequently had diabetes mellitus (42.4% vs. 22.8%, p=0.003), a history of stroke (12.1% vs. 3.4%, p=0.016), higher Killip class and "pain-to-balloon" time 7 [3; 16] vs. 4 [2.3; 8.25] hours, p=0.004. Binary logistic regression identified "pain-to-balloon" time as the most significant predictor of no-/slow-reflow phenomenon development [Odds Ratio (OR)=1.03; 95% CI: 0.95-0.996; p=0.02] and the proximal level of occlusion in infarct-related coronary artery. The incidence of in-hospital mortality was 6.1 times higher in the no-/slow-reflow group compared to the normal blood flow group [OR=6.102±0.433; 95% CI: 2.614-14.247; p<0.05].Conclusion. The development of the no-/slow-reflow phenomenon was observed in 2.8% of patients in clinical practice N. I. Pirogov City Clinical Hospital No.1. Its development was associated with an increase in the incidence of unfavorable outcome of the disease in the hospital. The total time of myocardial ischemia, the presence of diabetes mellitus, a history of stroke, and a higher Killip class of acute heart failure at admission were more often associated with the development of the no-/slow-reflow phenomenon. The proximal level of damage to the infarct-related artery and "pain-to-balloon" time were independent predictors of the no-/slowreflow phenomenon.

show abstract

Section: результатыunclassified

Clinical factors associated with the no/slow-reflow phenomenon in patients with acute coronary syndrome

Konstantinova,

Ilin,

Velikotskiy

et al. 2024

Racionalʹnaâ farmakoterapiâ v kardiologii

View full text Add to dashboard Cite

show abstract

Effects of etibatide combined with emergency percutaneous coronary intervention on blood perfusion and cardiac function in patients with acute myocardial infarction

et al. 2020

Pak J Med Sci

View full text Add to dashboard Cite

Objectives: To investigate the effects of etibatide combined with emergency percutaneous coronary intervention (PCI) on blood perfusion and cardiac function in acute myocardial infarction (AMI) patients. Methods: This was a prospective, randomized, controlled study. From November 2015 to June 2019, 196 patients with ST-segment elevation myocardial infarction (STEMI) undergoing emergency PCI admitted to Baoding First Central Hospital were enrolled. The 196 STEMI patients were randomly divided into experimental group and control group. In the experimental group, STEMI patients were treated with emergency PCI + etibatide; while in the control group, only PCI was performed. Observation indexes included: general data, myocardial perfusion and cardiac function indexes and major adverse cardiac events (MACE). Results: There was no significant difference in general data between the two groups (P > 0.05). The rate of ST-segment resolution (STR) in the experimental group was better than that in the control group (P < 0.05). In myocardial contrast echocardiography (MCE), higher peak intensity (PI) and shorter time-to-peak (TP) were observed in the experimental group compared with the control group (P < 0.05). The platelet aggregation rate was compared between the two group at the time points of before PCI, after PCI and two hour after drug withdrawal, and there was no significant change in the platelet aggregation rate of the control group between different time points (before PCI, after PCI and two hour after drug withdrawal); while the platelet aggregation rate of the experimental group was significantly lower after PCI and two hour after drug withdrawal than that before PCI (P < 0.05), and an obviously decreased platelet aggregation rate was found in the experimental group(P < 0.05). After three months of follow-up, there was one case of MACE in the experimental group and 1 case of MACE in the control group, without any difference in the incidence of MACE between the two groups (P > 0.05). Conclusion: Etibatide combined with emergency PCI could improve myocardial reperfusion and cardiac function in patients with acute STEMI without increasing the incidence of MACE. doi: https://doi.org/10.12669/pjms.37.1.2950 How to cite this:Hu Y, Qi F, Yu L, Geng W. Effects of etibatide combined with emergency percutaneous coronary intervention on blood perfusion and cardiac function in patients with acute myocardial infarction. Pak J Med Sci. 2021;37(1):185-190. doi: https://doi.org/10.12669/pjms.37.1.2950 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

show abstract

No reflow : quels facteurs prédictifs ?

Cited by 2 publications

References 33 publications

Clinical factors associated with the no/slow-reflow phenomenon in patients with acute coronary syndrome

Clinical factors associated with the no/slow-reflow phenomenon in patients with acute coronary syndrome

Effects of etibatide combined with emergency percutaneous coronary intervention on blood perfusion and cardiac function in patients with acute myocardial infarction

Contact Info

Product

Resources

About